Solid Biosciences to Present at Upcoming Scientific Conferences
Solid Biosciences (Nasdaq: SLDB) announced participation in key scientific conferences focusing on Duchenne muscular dystrophy. At the 16th International Congress of Neuromuscular Diseases on May 21-22 & 28-29, Dr. Perry Shieh will present findings from the Phase I/II IGNITE DMD trial of SGT-001 microdystrophin gene therapy, highlighting long-term biopsy data and safety evaluations. Additionally, at the Gene Therapy for Muscular Disorders conference from May 25-27, Dr. Carl Morris will discuss drug development strategies and participate in expert panels.
- None.
- None.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate at the following upcoming scientific conferences:
16th International Congress of Neuromuscular Diseases – May 21-22 & 28-29
Perry Shieh, MD, Professor of Neurology and Pediatrics at the University of California, Los Angeles, and an IGNITE DMD investigator, will present data from the ongoing Phase I/II IGNITE DMD clinical trial of SGT-001 microdystrophin gene therapy in patients with Duchenne, which were previously presented in a Company business update on May 14, 2021. This includes long-term biopsy data collected from patients 4-6 at the 2E14 vg/kg dose level. Analyses of the biopsies, taken 2 years, 1.5 years and 1-year post-dosing, respectively, indicate evidence of durable and widespread expression of the microdystrophin protein. The presentation will also include a one-year safety and efficacy evaluation of those patients and patients previously dosed at the 5E13 vg/kg level.
The digital poster, abstract number 747, “IGNITE-DMD: One-year Safety and Efficacy Evaluation of SGT-001 Microdystrophin Gene Therapy for DMD,” will be available to participants, on the congress website, for the duration of the meeting. Dr. Shieh will accept questions in the ePoster chat during the live congress dates.
To learn more about the event and registration, please visit: https://icnmd.org/registration/
Gene Therapy for Muscular Disorders – May 25-27
Carl Morris, Ph.D., Chief Scientific Officer at Solid Biosciences, will discuss pre-clinical and clinical drug development and outcome measures for patients with Duchenne, on Wednesday, May 26, 2021, at 8:40 a.m. ET.
Dr. Morris will also join gene therapy experts on two panels on Wednesday, May 26: “Overcoming Challenges to Demonstrate Durability in the Muscle,” at 9:20 a.m. ET and “Seeking Translatable Biomarkers,” at 2:10 p.m. ET.
To learn more about the event and registration, please visit: https://genetherapy-muscular.com/take-part/register/
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the ability of the Company to continue dosing patients in the IGNITE DMD trial, the implication of interim clinical data, the safety or potential treatment benefits of SGT-001 in patients with DMD, the Company’s expectations for reporting future data from the IGNITE DMD trial, the Company’s regulatory plans, the Company’s SGT-003 program, and timelines and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to or continue IGNITE DMD on the timeline expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; obtain and maintain the necessary approvals from investigational review boards at IGNITE DMD clinical trial sites and the IGNITE DMD independent data safety monitoring board; enroll patients in IGNITE DMD on the timeline expected; the Company’s dosing strategy; replicate in clinical trials positive results found in preclinical studies and earlier stages of clinical development; whether the interim data presented in this release will be predicative of the final results of the trial or will demonstrate a safe or effective treatment benefit of SGT-001; whether the methodologies, assumptions and applications we utilize to assess particular safety or efficacy parameters will yield meaningful statistical results; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; successfully optimize and scale its manufacturing process; obtain, maintain or protect intellectual property rights related to its product candidates; compete successfully with other companies that are seeking to develop Duchenne treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-001, SGT-003 and other product candidates, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com
FAQ
What is Solid Biosciences participating in on May 21-22 & 28-29, 2021?
What data will be presented at the 16th International Congress of Neuromuscular Diseases?
Who is presenting at the Gene Therapy for Muscular Disorders conference?
What is the focus of the IGNITE DMD clinical trial presented by Solid Biosciences?
How can I find more information about the upcoming conferences related to Solid Biosciences?
